The new Joint Clinical Assessment (JCA) promises big change in how products go to market. Are you ready for it? An upcoming live panel discussion — hosted by SwedenBio and PharmaLex (Cencora) — will share what you need to know about this new regulation. If you are launching a product into Europe and Sweden, this might interest you.
You don’t want to miss:
- Why the JCA matters and what you can expect from the framework
- Key insights about the JCA’s process from the pilot phase
- How the JCA impact patient access for your products
- The opportunities and challenges ahead
The 𝗘𝗨 𝗝𝗖𝗔 𝗽𝗿𝗼𝗰𝗲𝘀𝘀 as part of the 𝗘𝗨 𝗛𝗧𝗔 𝗥𝗲𝗴𝘂𝗹𝗮𝘁𝗶𝗼𝗻, seeking to substitute multiple country-specific clinical assessments and establish a more streamlined and transparent single market for health technologies, will pose both a threat and an opportunity for getting innovative medicines to patients in Europe and Sweden.
8.30 – 9.00 Breakfast and mingle
9.00 – 9.30 Panel discussion
9.30 – 9.45 Ask the experts
More info TBA